Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,298.70down ₹40.30 (1.72%)BSE ₹2,308.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,339.00.
30 Oct: open ₹2,336.00, high ₹2,337.30, low ₹2,291.30
52-week range of traded prices to 30 Oct 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹64,875 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.08
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,28,88751.5% delivered
Glenmark Pharmaceuticals orders, deals and press releases
594 filed, newest first. Page 12 of 12.
Sep 2008
25 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 25, 2008, titled "Glenmark dermatology line expands with recent U.S. FDA approval". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 11, 2008, titled " Glenmark to initiate Phase I studies for GBR 500 by filing its IND application with the US-FDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
28 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 28, 2008, titled "Glenmark posts consolidated revenue growth of 29.78% and Net profit growth of 101.88 % for Q1FY09; Consolidated revenue at Rs. 4664.50 Mn and Net Profit at Rs. 1153.76 Mn". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 15, 2008, titled "Glenmark's molecule for Neuropathic Pain, Osteoarthritis - GRC 10693, to enter Phase I trials; GRC 10693 is Glenmark's fifth molecule to enter clinical trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 02, 2008, titled "Glenmark establishes a new company in Poland and acquires a product portfolio of 7 established brands, Acquistion will help Glenmark accelerate its Polish business". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2008
20 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 20, 2008, titled "Glenmark Generics Launches Trandolapril Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2008
30 May · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated May 30, 2008, titled "Glenmark Generics receives three ANDA approvals - Portfolio of 32 products for the US market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 May · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated May 05, 2008, titled "Glenmark launches topical antifungal cream - Onabet". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
28 Apr · Business
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of Management Discussion & Analysis for fourth quarter/year of the Financial Year 2007-08 ended March 31st, 2008 and a copy of the press release dated April 28, 2008 titled "Glenmark posts a consolidated revenue growth of 62.56 per cent and consolidated revenues of Rs. 5822.35 million for Q4 FY08". A copies of the Management Discussion & Analysis and Press Release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 10, 2008, titled "Glenmark completes preclinical development for initiating Phase I trials for GBR 500 - a monoclonal antibody for inflammation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 01, 2008, titled "Glenmark implements Business Re-organisation; Begins a new era of accelerated growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2008
17 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 17, 2008, titled "Glenmark launches Clobetasol from its niche dermatology pipeline". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 13, 2008, titled "Glenmark launches Nabumetone and Hydroxyzine Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that regarding a press release dated March 4, 2008, titled "Glenmark establishes presence in Romania". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2008
21 Feb · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated February 21, 2008, titled "Glenmark's molecule for Rheumatoid Arthritis-GRC 4039, enters Phase I trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Feb · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated February 06, 2008, titled "Glenmark's receives USD 15 million as milestone payments from Forest for Oglemilast, GRC 3886". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Feb · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated February 01, 2008, titled "Glenmark Pharmaceuticals to get back the Global Rights to Melogliptin, GRC 8200 from Merck Serono". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
28 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 28, 2008, titled "Glenmark receives US FDA approval for its state-of-the-art semi-solids manufacturing plant at Baddi". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jan · Business
Glenmark Pharmaceuticals Ltd. has submitted to the exchange a copy of Management Discussion & Analysis for third quarter of the Financial Year 2007-08 ended 31st December, 2007 and Press Release dated January 21, 2008 titled "Glenmark posts a consolidated revenue growth of 53.56 per cent and consolidated revenues of Rs. 6850.77 million for Q3 FY08" A copies of the Management Discussion & Analysis and Press Release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 14, 2008, titled "Glenmark's lead molecule for Type II Diabetes GRC 8200 receives "Melogliptin" as its International Non-proprietary Name". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2007
13 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 12, 2007, titled "Glenmark Confirms ANDA Filing with a Paragraph IV Certification for Tarka (R) Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2007
28 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 28, 2007, titled "Glenmark announces plans to expand presence in Nigeria". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 07, 2007, titled "Glenmark announces plan to reorganize businesses into Specialty and Generics". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2007
31 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 31, 2007, titled "Glenmark posts a consolidated revenue growth of 50.16 per cent and consolidated revenues of Rs. 3839.47 million for Q2 FY08". A copy of the press release and Management Discussion & Analysis shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements) For more details click here.30 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 30, 2007, titled "Lilly and Glenmark Pharmaceuticals Announce License Agreement". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 29, 2007, titled "Oglemilast, Glenmark's lead molecule for Asthma / COPD receives US FDA nod to initiate further Phase II trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 25, 2007, titled "Glenmark offers the widest topical dermatology products in South Africa". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 10, 2007, titled "Glenmark receives US FDA approval for the first generic version of Trileptal-Oxcarbazepine-Shared Exclusivity". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.5 Oct · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated October 05, 2007, titled "Glenmark wins Emerging Company Of The Year 2007 at The Economic Times Awards for Corporate Excellence". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2007
26 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 26, 2007, titled "Glenmark receives MHRA, UK approval for its state-of-the-art semi-solids manufacturing plant at Baddi". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Sep · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated September 10, 2007, titled "Glenmark receives US FDA approval for the first generic version of Coreg - Carvedilol". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
30 Jul · Business
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the presentation made at the analyst meet titled "Management Discussion and Analysis for First Quarter of the Financial Year 2007-08 ended 30th June, 2007". Further, the company has also informed the Exchange regarding a press release dated July 30, 2007, titled "Glenmark posts for Q1 FY08, a consolidated revenue growth of 88 per cent and consolidated profits of Rs.3594.24 million". The details of the both shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 19, 2007, titled "Glenmark purchases rights to two therapeutic antibodies from chromos". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 03, 2007, titled "Glenmark receives tentative US FDA approval for Terbinafine Hydrochloride tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 02, 2007, titled "Glenmark receives tentative US FDA approval for its ANDA for Topiramate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2007
29 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 29, 2007, titled "Glenmark receives US FDA approval for Ondansetron IR and Ondansetron ODT tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.21 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 21, 2007, titled "Glenmark receives tentative US FDA approval for its ANDA for Terbinafine HCL tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
28 May · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "Glenmark Pharmaceuticals S.A. (GPSA), the Swiss subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), has entered Phase II clinical trials for GRC 6211 in Europe". A copy of the press release dated May 28, 2007, titled "Glenmark's lead candidate for pain, GRC 6211, to enter Phase II trials in Europe" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 May · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated May 16, 2007, titled "Glenmark receives US FDA approval to market generic Pravastatin Sodium, Naproxen Sodium and Naproxen". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
25 Apr · Business
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the presentation made at the analyst meet titled "Management Discussion and Analysis for Fourth Quarter and Financial Year 2006-07 ended 31st March, 2007". Further, the company has also informed the Exchange regarding a press release dated April 25, 2007, titled "Glenmark posts 64% consolidated revenue growth with an increase of 254% in consolidated net profit for FY07". The details of the both shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2007
28 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 28, 2007, titled "Glenmark Confirms ANDA Filing with a Paragraph IV Certification for Zetia (R) Tablets". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release towards conclusion of deal by Glenmark Holding SA, Switzerland a wholly owned subsidiary of the Company, to acquire a majority shareholding (>90%) of Medicamenta a.s, a pharmaceutical marketing and manufacturing Company in the Czech Republic. The copy of the press release dated March 26, 2007, titled "Glenmark concludes deal to acquire Medicamenta a.s., a pharmaceutical marketing and manufacturing company in the Czech Republic" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Mar · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 12, 2007, titled "Dyax Corp. and Glenmark Enter Into Funded Research Agreement for Discovery of Therapeutic Antibodies". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
23 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release, dated January 23, 2007, titled "Glenmark posts for Q3 FY07 consolidated revenue growth of 118% and consolidated profits of Rs. 1889.2 million." The details of the press release and Management Discussion & Analysis shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.